0001493152-21-014308 | 10-Q | XBRL Viewer

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Apr. 30, 2021	Jun. 07, 2021
Cover [Abstract]
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Apr. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		145,638,459
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ in Thousands	6 Months Ended
Apr. 30, 2021 USD ($)
Common Stock Purchase Warrants And Warrant Liability
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	3 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Issued	5 years
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	4 years 10 months 21 days
Aggregate Intrinsic Value, Beginning	$ 110,640
Aggregate Intrinsic Value, Ending	$ 809,752

Label	Element	Value
Common stock warrant liability	ADXS_CommonStockWarrantLiability	$ 17,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability	17,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability	17,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability	29,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability	4,931,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability	4,931,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability	4,902,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability	29,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability	4,902,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability
Common stock warrant liability	ADXS_CommonStockWarrantLiability	4,931,000
Common stock warrant liability	ADXS_CommonStockWarrantLiability	$ 17,000
Expiration date description	ADXS_WarrantsExpirationDescription	5 years after the date such warrants become exercisable, if ever
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	July 2019 Public Offering
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	Other Warrants
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	September 2018 Public Offering
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	Other warrants
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	September 2018 Public Offering
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	July 2019 Public Offering
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	November 2020 Public Offering
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	April 2021 Registered Direct Offering (Accompanying Warrants)
Type of Financing	ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings	April 2021 Private Placement (Private Placement Warrants)
WarrantExercises	ADXS_WarrantExercises	$ 2,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises	7,000
WarrantExercises	ADXS_WarrantExercises	2,579,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises	2,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises	1,185,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises	2,586,000
WarrantExercises	ADXS_WarrantExercises	1,999,999,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises	11,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises	1,174,000
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises
WarrantExercises	ADXS_WarrantExercises
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares	7,390,000
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares	26,416
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares	7,500
Warrant exercises, shares	ADXS_WarrantExercisesShares	11,037,435
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Warrant exercises, shares	ADXS_WarrantExercisesShares
Capital description	ADXS_CapitalDescription	The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.
Write off of the remaining right of use asset	ADXS_WriteOffOfRemainingRightOfUseAsset	$ 4,500,000
Early termination of lease payment	ADXS_EarlyTerminationOfLeasePayment	$ 1,000,000
Expiration of patents description	ADXS_ExpirationOfPatentsDescription	The expiration dates of the existing patents range from 2021 to 2040.
Operating lease liabilities	ADXS_IncreaseDecreaseInOperatingLeaseLiabilities	$ (389,000)
Operating lease liabilities	ADXS_IncreaseDecreaseInOperatingLeaseLiabilities	(397,000)
Net payment of lease termination fee	ADXS_NetPaymentOfLeaseTerminationFee	817,000
NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability	ADXS_NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability	1,116,000
NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability	ADXS_NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	ADXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding	7 years 7 months 13 days
write off of lease liability	ADXS_WriteOffOfLeaseLiability	$ 5,600,000
Loss on write-down of intangible assets	ADXS_LossOnWritedownOfIntangibleAssets	69,000
Loss on write-down of intangible assets	ADXS_LossOnWritedownOfIntangibleAssets
Software	ADXS_FiniteLivedSoftwareGross	117,000
Software	ADXS_FiniteLivedSoftwareGross	117,000
Employee stock purchase plan expense	ADXS_EmployeeStockPurchasePlanExpense
Employee stock purchase plan expense	ADXS_EmployeeStockPurchasePlanExpense	1,000
Warrant liability reclassified into equity	ADXS_WarrantLiabilityReclassifiedIntoEquity
Warrant liability reclassified into equity	ADXS_WarrantLiabilityReclassifiedIntoEquity	$ 2,000
Pre-funded warrants to purchase common shares	ADXS_PrefundedWarrantsToPurchaseCommonShares	7,671,937
Pre-funded warrants to purchase common shares	ADXS_PrefundedWarrantsToPurchaseCommonShares	7,671,937
Pre-funded warrants to purchase common shares	ADXS_PrefundedWarrantsToPurchaseCommonShares	7,671,937
Funding milestone payment	ADXS_FundingMilestonePayment	$ 2,337,500
OS Therapies LLC [Member]
Milestone achievement, description	ADXS_MilestoneAchievementDescription	The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.
Milestone achievement, description	ADXS_MilestoneAchievementDescription	The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.

Print Document View Excel Document
Cover Document and Entity Information Notes Details Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) Uncategorized Uncategorized Items - adxs-20210430.xml All Reports